State of the science of adherence in pre-exposure prophylaxis and microbicide trials

Journal of Acquired Immune Deficiency Syndromes

Volumn 61, Issue 4, 2012, Pages 490-498

  Muchomba, Felix M ^a   Gearing, Robin E ^a   Simoni, Jane M ^b   El Bassel, Nabila ^a  

^a Columbia University ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

adherence; microbicides; pre exposure prophylaxis; review

Indexed keywords

CARRAGEENAN; CELLULOSE SULFATE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; MICROBICIDE; NONOXINOL 9; PRO 2000; TENOFOVIR DISOPROXIL;

COCHRANE LIBRARY; COMMUNITY; HEALTH PROMOTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDLINE; MOTIVATION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCINFO; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; SEXUALITY; SYSTEMATIC REVIEW; TREATMENT REFUSAL;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; BIOMEDICAL RESEARCH; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84870295000     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31826f9962     Document Type: Review

References (54)

1. Cohen MS, Gay C, Kashuba AD, et al. Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med. 2007;146:591-601. (Pubitemid 351650540)
2. Garcia-Lerma JG, Paxton L, Kilmarx PH, et al. Oral pre-exposure prophylaxis for HIV prevention. Trends Pharmacol Sci. 2010;31:74-81.
3. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet. 2008;372:585-599.
4. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet. 2007;369:787-797. (Pubitemid 46335821)
5. McGowan I. Microbicides for HIV prevention: reality or hope? Curr Opin Infect Dis. 2010;23:26-31.
6. Karim SS, Karim QA. Antiretroviral prophylaxis: a defining moment in HIV control. Lancet. 2011;378:e23-e25.
7. Kippax S, Stephenson N. Beyond the distinction between biomedical and social dimensions of HIV prevention through the lens of a social public health. Am J Public Health. 2012;102:789-799.
8. Grant RM. Antiretroviral agents used by HIV-uninfected persons for prevention: pre-and postexposure prophylaxis. Clin Infect Dis. 2010;50 (suppl 3):S96-S101.
9. Karim SS, Kashuba AD, Werner L, et al. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011;378:279-281.
10. Simoni JM, Amico KR, Pearson CR, et al. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. Curr Infect Dis Rep. 2008;10:515-521.
11. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107. (Pubitemid 30482715)
12. Mills EJ, Nachega JB, Bangsberg DR, et al. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. PLoSMed. 2006;3:e438.
13. Mugavero M, Ostermann J, Whetten K, et al. Barriers to antiretroviral adherence: the importance of depression, abuse, and other traumatic events. AIDS Patient Care STDS. 2006;20:418-428. (Pubitemid 43993096)
14. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(suppl 2):S171-S176. (Pubitemid 32268984)
15. Fogarty L, Roter D, Larson S, et al. Patient adherence to HIV medication regimens: a review of published and abstract reports. Patient Educ Couns. 2002;46:93-108. (Pubitemid 34175086)
16. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34:281.
17. Posse M, Meheus F, Van Asten H, et al. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health. 2008;13:904-913. (Pubitemid 351813518)
18. Kagee A, Remien R, Berkman A, et al. Structural barriers to ART adherence in Southern Africa: challenges and potential ways forward. Glob Public Health. 2011;6:83-97.
19. Williams AB, Amico KR, Bova C, et al. A proposal for quality standards for measuring medication adherence in research. AIDSBehav. 2012:1-14. [epub ahead of print; DOI:10.1007/s10461-012-0172-7].
20. Lukens EP, McFarlane WR. Psychoeducation as evidence-based practice: considerations for practice, research, and policy. Brief Treat Crisis Interv. 2004;4:205.
21. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168-1174.
22. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011;25:957.
23. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One. 2008;3:e1474.
24. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS One. 2008;3:e3784.
25. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010;376:1329-1337.
26. Microbicide Trials Network (MTN). Microbicide trials network statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. Microbicide Trials Network Web site. Available at: http://www.mtnstopshiv.org/node/3909. Accessed December 17, 2011.
27. Peterson L, Nanda K, Opoku BK, et al. SAVVY®(C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One. 2007;2:e1312.
28. Richardson BA, Lavreys L, Martin HL Jr, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394.
29. Roddy RE, Zekeng L, Ryan KA, et al. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection. JAMA. 2002;287:1117-1122. (Pubitemid 34252080)
30. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1977-1987.
31. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002;360:971-977. (Pubitemid 35284107)
32. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008;359:463-472.
33. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992;268:477-482.
34. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504-510. (Pubitemid 28384883)
35. Baeten J, Celum C. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract MOAX0106.
36. Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to anti-retroviral pre-exposure prophylaxis (PrEP) against HIV infection among HIV-serodiscordant couples as determined by multiple measures: preliminary data from the partners PrEP study. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 27-March 2, 2011. Paper 488.
37. Family Health International. FEM-PrEP project. FHI 360 Web site. Available at: http://www.fhi360.org/en/Research/Projects/FEM-PrEP. htm. Accessed December 17, 2011.
38. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
39. Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLoS Clin Trials. 2007;2:e27.
40. Thigpen M, Kebaabetswe P, Smith D, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy, July 17-20, 2011. Abstract WELBC01.
41. Wilson IB, Carter AE, Berg KM. Improving the self-report of HIV anti-retroviral medication adherence: is the glass half full or half empty? Curr HIV/AIDS Rep. 2009;6:177-186.
42. Gearing RE, Townsend L, MacKenzie M, et al. Reconceptualizing medication adherence: six phases of dynamic adherence. Harv Rev Psychiatry. 2011;19:177-189.
43. Ziguras SJ, Stuart GW. A meta-analysis of the effectiveness of mental health case management over 20 years. Psychiatr Serv. 2000;51:1410-1421.
44. El-Bassel N, Gilbert L, Witte S, et al. Couple-based HIV prevention in the United States: advantages, gaps, and future directions. J Acquir Immune Defic Syndr. 2010;55:S98.
45. Martire LM, Schulz R, Helgeson VS, et al. Review and meta-analysis of couple-oriented interventions for chronic illness. Ann Behav Med. 2010; 40:325-342.
46. Atkinson AJ, Colburn WA, DeGruttola VG, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89-95. (Pubitemid 32225406)
47. Wallace A, Thorn M, Maguire RA, et al. Assay for establishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis. 2004;31:465.
48. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception. 2007;76:53-56. (Pubitemid 46950884)
49. Gearing RE, El-Bassel N, Ghesquiere A, et al. Major ingredients of fidelity: a review and scientific guide to improving quality of intervention research implementation. Clin Psychol Rev. 2011;31:79-88.
50. Microbicide Trials Network (MTN). ASPIRE (MTN-020). Microbicide Trials Network Web site. Available at: http://www.mtnstopshiv.org/-news/studies/mtn020. Accessed March 1, 2012.
51. Family Health International, The Centre for the AIDS Programme of Research in South Africa. Factsheet: CAPRISA 004 and adherence to study product. Research Triangle Park, NC USA: FHI and the Centre for the AIDS Programme of Research in South Africa; 2010:4.
52. Seyama L. Community engagement in HPTN 035: MTN annual meeting, April 21, 2009, Arlington, Virginia USA. MTN 2009 Annual Meeting Presentations Web site. Available at: http://www.mtnstopshiv.or-g/2009annualmeeting. Accessed February 1, 2012.
53. Pool R, Montgomery CM, Morar NS, et al. A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: The microbicides development programme. PloS one. 2010;5:e11600.
54. Family Health International. Technical report: Behavioral and social science support to CONRAD phase III clinical trial of cellulose sulfate 6% gel. Research Triangle Park, NC USA: FHI 360; 2008:89.